CTOs on the Move

Xealth

www.xealth.io

 
Xealth enables healthcare teams to order digital content and services as easily as they do medications today.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Xealth raised $11M on 03/27/2019

Similar Companies

Boys Town National Research Hospital

Boys Town National Research Hospital is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SonderMind

SonderMind makes it easier for people who are searching for a mental health professional to find licensed therapists who are available for in-person or video sessions.

Medical Business bureau

Medical Business bureau is a Park Ridge, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Villa Healthcare

We`re Villa Healthcare, and we make people better. Of course, we`re focused on quality care and good outcomes. But we`re here to do so much more. At Villa, we offer the very best in post-acute and long-term care. Our focus is providing exceptional clinical services by people who truly care, in an environment that promotes healing and wellness. Villa`s leadership has a vision of rising above the status quo—of never settling, and of shattering the old image of this industry. We`ve always wanted to be a part of something greater, and we`ve made that a reality by both making people better and by creating and sharing opportunities. We currently have 22 facilities in four different states*. As Villa has grown, we have redoubled our efforts to ensure that the Villa experience is the same at every location. By extensively renovating our centers and hiring the best people we can, we are making our mark in the world of healthcare. It`s how Villa makes people better.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.